The Effect of Antiviral Therapy on Serum Cholesterol Levels in Chronic Hepatitis C

Eun Sun Jang, Ji-Eon Won, Jae Il Jung, Sang-Hyub Lee, Jin Wook Kim, and Sook-Hyang Jeong

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Background/Aims: The aims of this study were to evaluate the effect of antiviral therapy on serum total cholesterol (TC) levels and to investigate the factors related to serum TC changes in chronic hepatitis C (CHC) patients. Methods: A total of 94 CHC patients, the majority of whom were infected with genotype 1 or 2 and were receiving antiviral therapy, were consecutively enrolled. TC levels before treatment, at week 4, at the end of treatment (EOT), and at 24 weeks after the EOT were analyzed, along with factors related to pre- and post-treatment TC levels. Results: Pretreatment TC levels in the sustained virologic response (SVR) group (167±3.6 mg/dL) and the non-SVR group (158±8.3 mg/dL) were similar, and both decreased during antiviral therapy. The TC levels at 24 weeks after the EOT significantly increased in the SVR group (183±4.7 mg/dL), but not in the non-SVR group (160±7.1 mg/dL, p=0.044) after adjusting for the pretreatment TC levels. The grade of hepatic fibrosis, as measured by the METAVIR score or the aspartate aminotransferase-platelet ratio index (APRI), but not viral load (p=0.119), was an independent variable associated with the pretreatment TC levels (METAVIR score, p=0.011; APRI, p=0.033). After adjusting for the presence of a SVR by longitudinal data analysis using generalized estimating equations, the independent variable APRI was associated with the serum TC level after antiviral therapy (p=0.084). Conclusions: Serum TC levels increased in the SVR group after antiviral therapy for CHC; however, this was probably due to an improvement in liver fibrosis rather than the eradication of virus. (Gut Liver 2011;5:356-362)

Key Words: Chronic hepatitis C; Therapeutics; Cholesterol; Fibrosis; Sustained virologic response

INTRODUCTION

Because the liver plays a fundamental role in lipid metabolism, serum total cholesterol (TC) level decreases among patients with chronic liver disease as severity of liver disease increases. Chronic hepatitis C virus (HCV) infection induces more remarkable decrease of TC and lipoprotein levels when compared to other types of liver disease, even in the early stage of HCV infection, prior to development of liver cirrhosis. Many investigators have documented the direct effects of HCV on lipid metabolism. Among patients infected with genotype 3, low TC level correlated with high HCV ribonucleic acid (RNA) level and a high degree of hepatic steatosis. Moreover, hypocholesterolemia was reversed after antiviral therapy in sustained virologic responders infected with genotype 3 HCV, and high TC levels prior to antiviral therapy may indicate good treatment outcomes.

However, a study of the effect of HCV infection or of antiviral therapy on cholesterol metabolism has been limited in areas where genotype 1 or 2 is prevalent, such as in the Asia-Pacific area. In addition, clinical factors correlated with pretreatment serum TC levels in chronic hepatitis C (CHC) and predictors of change of TC levels after antiviral therapy have not been clearly elucidated, particularly in non-3 genotype infection.

The aims of this study were to evaluate the effect of antiviral therapy on serum TC level according to antiviral response, and to investigate factors related to pretreatment and post-treatment TC levels in CHC patients.

MATERIALS AND METHODS

1. Patients

A total of 94 CHC patients treated with interferon (IFN)-α,
pegylated IFN-α-2a, or α-2b combined with ribavirin and completely evaluated for virologic response were consecutively enrolled at Seoul National University Bundang Hospital between October 2003 and October 2008. CHC was defined by detectable serum anti-HCV antibodies, as well as HCV RNA for more than 6 months. Exclusion criteria included chronic liver disease caused by other than HCV (i.e., hepatitis B viral hepatitis, nonalcoholic steatohepatitis, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, Wilson's disease), human immunodeficiency virus infection, or hepatocellular carcinoma.

2. Methods

Retrospective review of electronic medical records and meticulous data collection were performed. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital.

Presence of liver cirrhosis was evaluated by ultrasonography, computed tomography, and/or liver biopsy. Among the total of 94 patients, 60 cases underwent liver biopsy; slides were reviewed by an experienced liver pathologist who was blinded to the clinical course, according to the METAVIR scoring system. As a simple and validated serum marker of hepatic fibrosis, aspartate aminotransferase (AST)-platelet ratio indexes (APRI) [AST(ULN)×100/platelet(×10⁹/L)] were calculated.

Treatment responses were defined as early virologic response (EVR), a decrease of more than 2 log₁₀ serum HCV RNA at week 12 of treatment, and end-of-treatment response (ETR), undetectable serum HCV RNA at week 24 (for genotype 2 or 3) or at week 48 (for genotype 1 or 4) of antiviral therapy. Sustained virologic response (SVR) was defined as continued undetectable HCV RNA at 24 weeks after end-of treatment (EOT). Serum TC, alanine aminotransferase, albumin, and APRI were recorded at pretreatment, week 4 of treatment, EOT, and 24 weeks after treatment.

### Table 1. Comparison of the Clinical Characteristics of the Sustained Viral Response (SVR) Group and the Non-SVR Group after Antiviral Therapy for Chronic Hepatitis C

| Characteristic            | Overall [n=94] | SVR (+) [n=72] | SVR (-) [n=22] | p-value |
|---------------------------|---------------|----------------|----------------|---------|
| Age, yr                   | 53.4±11.2     | 52.6±11.3      | 55.9±10.9      | 0.226   |
| Male, n (%)               | 52 (55.3)     | 45 (62.5)      | 7 (31.8)       | 0.011   |
| BMI, kg/m²                | 24.0±2.7      | 23.9±2.7       | 24.1±2.6       | 0.866   |
| Liver cirrhosis, n (%)    | 23 (24.5)     | 13 (18.1)      | 10 (45.5)      | 0.009   |
| Pathology                 |               |                |                |         |
| Fibrosis, Grade 3/4, n/N (%)| 15/60 (25.0) | 11/45 (24.4)  | 4/15 (26.7)    | 1.000   |
| Laboratory findings       |               |                |                |         |
| Platelet, ×10⁹/μL         | 173.0±81.0    | 181.6±83.8     | 144.7±64.8     | 0.062   |
| Total cholesterol, mg/dL  | 164.8±32.9    | 166.8±30.9     | 158.3±39.0     | 0.290   |
| Albumin, g/dL             | 4.1±0.3       | 4.1±0.3        | 4.0±0.4        | 0.086   |
| ALT, IU/L                 | 112.2±93.9    | 118.3±100.3    | 92.2±67.0      | 0.257   |
| Prothrombin time, INR     | 1.07±0.12     | 1.06±0.11      | 1.12±0.13      | 0.050   |
| Genotype 1, n (%)         | 38 (40.4)     | 26 (36.1)      | 12 (54.5)      | 0.123   |
| HCV RNA, log IU/mL        | 5.5±0.8       | 5.4±0.8        | 5.9±0.5        | 0.049   |
| APRI                      | 1.4±1.1       | 1.4±1.2        | 1.5±1.1        | 0.719   |
| Treatment Type            |               |                |                | 0.782   |
| PegIFN α-2a, n (%)        | 25 (26.6)     | 20 (27.8)      | 5 (22.7)       |         |
| PegIFN α-2b, n (%)        | 41 (43.6)     | 30 (41.7)      | 11 (50.0)      |         |
| Conventional IFN, n (%)   | 28 (29.8)     | 22 (30.6)      | 6 (27.3)       |         |
| Completion, n (%)         | 71 (75.5)     | 60 (83.3)      | 11 (50.0)      | 0.001   |
| Responses                 |               |                |                |         |
| RVR (n=46), n (%)         | 28 (60.9)     | 24 (64.9)      | 4 (44.4)       | 0.284   |
| EVR (n=86), n (%)         | 79 (91.9)     | 65 (98.5)      | 14 (70.0)      | <0.001  |
| ETR (n=89), n (%)         | 76 (85.4)     | 63 (92.6)      | 13 (61.9)      | 0.002   |

All results for continuous variables are shown as mean±SD. BMI, body mass index; ALT, alanine aminotransferase; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, aspartate aminotransferase-platelet ratio index; PegIFN, pegylated interferon; IFN, interferon; RVR, rapid virologic response; EVR, early virologic response; ETR, end of treatment response.
EOT.

3. Statistical analysis

Student’s t-tests and Mann-Whitney U-tests for continuous variables, χ² and Fisher’s exact tests for categorical variables were used for univariate analysis in the search for predictors of SVR. Variables with p-values of <0.1 by univariate analysis were included in a multiple binary logistic regression model. The changes of serum TC level and APRI scores from pretreatment to week 4 of treatment, EOT, and 24 weeks after EOT were analyzed by repeated measures analysis of variance (ANOVA). To determine independent effects of clinical variables associated with serum TC after antiviral therapy, univariable and multivariable generalized estimating equation (GEE) analyses were used with adjustment of time dependent changes of serum TC levels. All statistical evaluations were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). p-values of <0.05 were considered statistically significant.

RESULTS

1. Clinical characteristics of patients

The mean age of the 94 eligible patients was 53 years, and 55% were males. The major viral genotypes were 1 (41%) and 2 (52%). Only 1 (1.1%) patient had genotype 3, and 2 (2.1%) had genotype 6. Among 60 liver biopsy specimens, 25% revealed fibrosis grade 3 or 4 using the METAVIR scoring system, and APRI scores showed significant correlation with grades of fibrosis (γ=0.549, p<0.001). Therefore, APRI score was confirmed as a significant indicator of fibrosis in our study.

Twenty-three (24.5%) patients were withdrawn from antiviral therapy due to side effects (n=20) and lack of EVR (n=3). Of 94 patients, 72 (76.6%) had SVR: 26 of 38 (68.4%) in genotype 1, 46 of 56 (82.1%) in genotype non-1. Comparison of clinical characteristics between the SVR group and the non-SVR group is shown in Table 1. Pretreatment TC levels in the SVR group were not different from those in the non-SVR group (p=0.290, Table 1), while being male, having a pretreatment HCV RNA titer <5.5 log IU/mL, and completion of antiviral therapy were significant independent factors for predicting SVR in our patients by logistic regression analysis (male, odds ratio [OR] 47.2, 95% confidence interval [CI] 2.38 to 936.76, p=0.012; pretreatment HCV RNA <5.5 log IU/mL, OR 20.3, 95% CI 1.21 to 341.8, p=0.037; completion of antiviral therapy, OR 34.2, 95% CI 1.91 to 611.7, p=0.016; data not shown).

2. Changes of serum TC levels in the SVR and the non-SVR groups

TC levels were significantly changed during and after antiviral therapy (Fig. 1). Serum TC levels decreased at week 4 of treatment and remained at the decreased levels until EOT in both SVR and non-SVR groups. At 24 weeks after EOT, the SVR group revealed significantly increased TC levels (183±4.7 mg/dL) compared to pretreatment TC levels (167±3.6 mg/dL), while such
an increase was not observed in the non-SVR group (Fig. 1A). The changes of TC levels during and after antiviral therapy were not significantly different between SVR and non-SVR group by repeated measure ANOVA analysis (p=0.131). However, TC level of SVR group was higher than non-SVR group although it was not significant (Table 1). Thus, we performed another repeated measure ANOVA after adjusting for pretreatment TC level to determine whether the change of TC levels from pretreatment to 24 weeks after EOT in SVR was different from that of non-SVR group. As a result, estimated serum TC levels after antiviral therapy significantly increased in SVR group compared to non-SVR group after adjusting for pretreatment TC (p=0.044, Fig. 1B).

3. Clinical variables associated with pretreatment TC levels in CHC

As shown in Table 2, pretreatment TC levels were not associated with the HCV genotype or viral load. However, pretreatment serum TC levels declined significantly as Child-Pugh score increased or as platelet count decreased (Child-Pugh score, $\beta$=−21.42, 95% CI -35.6 to -5.25, p=0.010; platelet count, $\beta$=0.11, 95% CI 0.04 to 0.19, p=0.004; Table 2). In addition, METAVIR grade of fibrosis and APRI score were found to be significantly correlated with pretreatment serum TC levels in CHC patients (grade of fibrosis, $\beta$=−10.11, 95% CI -17.8 to -2.41, p=0.011; APRI, $\beta$=−5.07, 95% CI -9.73 to -0.41, p=0.033; Table 2). Therefore, pretreatment TC levels of CHC patients showed significant negative association with their severity of hepatic fibrosis.

4. Clinical variables associated with the change of serum TC levels after antiviral therapy in CHC

As mentioned above, serum TC levels at 24 weeks after antiviral therapy for CHC significantly increased in the SVR group (Fig. 1). To evaluate independent variables associated with serum TC levels after adjusting for the time-dependent changes, longitudinal analyses using GEE were performed. According to univariable analyses, serum TC level was significantly affected by fibrosis markers including platelet count ($\beta$=0.15, 95% CI 0.01 to 0.29, p=0.034; Table 3), METAVIR grade ($\beta$=−9.59, 95% CI -16.93 to -2.25, p=0.010; Table 3), Child-Pugh score ($\beta$=−24.18, 95% CI -38.65 to -9.72, p=0.001; Table 3), and APRI score ($\beta$=−7.81, 95% CI -13.85 to -1.78, p=0.011; Table 3). In multivariable analysis including APRI and SVR, the significant variables included platelet count, METAVIR grade, and Child-Pugh score (Table 3).

| Variable          | Regression coefficient ($\beta$) | 95% CI        | p-value |
|-------------------|---------------------------------|--------------|---------|
| Age, yr           | -0.46                           | -1.00 to 0.08| 0.096   |
| Female            | -0.64                           | -1.36 to 0.09| 0.122   |
| BMI, kg/m$^2$     | -2.11                           | -4.50 to 0.29| 0.084   |
| HCV RNA titer, log IU/mL | 8.20                           | -2.14 to 18.54| 0.119   |
| Genotype 1        | -1.64                           | -14.42 to 11.15| 0.800   |
| Platelet count, $\times 10^3/\mu$L | 0.11                           | 0.04 to 0.19  | 0.004   |
| METAVIR grade     | -10.11                          | -17.80 to -2.41| 0.011   |
| Child-Pugh score  | -21.42                          | -35.60 to -5.25| 0.010   |
| APRI              | -5.07                           | -9.73 to -0.41| 0.033   |

CI, confidence interval; BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, aspartate aminotransferase-platelet ratio index.

Table 3. Clinical Variables Associated with the Serum Total Cholesterol Level after Antiviral Therapy Identified Using Generalized Estimating Equations with an Adjustment for Time-Dependent Changes in the Total Cholesterol Level

| Variable          | Regression coefficient ($\beta$) | 95% CI        | p-value |
|-------------------|---------------------------------|--------------|---------|
| Age, yr           | -0.23                           | -0.74 to 0.29| 0.390   |
| Female            | 1.80                            | -11.11 to 14.70| 0.785   |
| BMI, kg/m$^2$     | -1.03                           | -3.48 to 1.41| 0.406   |
| HCV RNA titer, log IU/mL | 5.78                           | -5.54 to 17.10| 0.317   |
| Genotype 1        | -6.23                           | -18.87 to 6.40| 0.333   |
| Platelet count, $\times 10^3/\mu$L | 0.15                           | 0.01 to 0.29  | 0.034   |
| METAVIR grade     | -9.59                           | -16.93 to -2.25| 0.010   |
| Child-Pugh score  | -24.18                          | -38.65 to -9.72| 0.001   |
| APRI              | -7.81                           | -13.85 to -1.78| 0.011   |
| SVR               | 14.44                           | -0.69 to 29.58| 0.061   |

These variables show significant correlation with serum cholesterol by univariable analyses. The significant variables in univariable analyses including platelet count, METAVIR grade and Child-Pugh score are excluded in the multivariable model because they can be representative as APRI. CI, confidence interval; BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, aspartate aminotransferase-platelet ratio index; SVR, sustained virologic response.

*Model was adjusted for APRI and SVR.
95% CI -38.65 to -9.72, \( p=0.001 \); Table 3), and APRI (\( \beta=-7.81 \),
95% CI -13.85 to -1.78, \( p=0.011 \); Table 3). Moreover, APRI was
an independent factor associated with serum TC levels by the
multivariable GEE analysis (\( \beta=-8.04 \), 95% CI -14.43 to -1.66,
\( p=0.014 \); Table 3). In this multivariable model, the eradication of
viruses (SVR) was also included because it was associated with
serum TC levels with \( p \)-value of less than 0.1.

The changes of APRI during and after antiviral therapy for
CHC were different from SVR and non-SVR group (\( p=0.05 \), Fig.
2A). At 24 weeks after EOT, SVR group revealed significantly
decreased APRI (0.46±0.06) compared to the pretreatment APRI
(1.36±0.14). The changes of APRI were different more signifi-
cantly between SVR and non-SVR groups after adjusting for
pretreatment APRI (\( p<0.001 \), Fig. 2B). Therefore, the APRI con-
tinuously decreased during and after antiviral therapy, while
serum TC levels decreased during antiviral therapy and then
increased after EOT in SVR group.

DISCUSSION

In the present study, serum TC level significantly increased at
24 weeks after EOT among those in SVR group after antiviral
therapy for CHC, but not in non-SVR group. Pretreatment and
post-treatment TC levels were both independently associated
with grade of hepatic fibrosis, while achievement of SVR was
marginal associated with post-treatment TC levels. These re-
sults suggest that the change of serum TC levels according to
antiviral therapy may be caused by improvement of hepatic
fibrosis secondary to viral eradication rather than by the elimi-
nation of direct effects of HCV to the cholesterol metabolism in
infected hepatocytes.

Serum TC level represents total amount of endogeneously
synthesized and exogeneously absorbed cholesterols, which are
transported into blood by binding to lipoproteins including very
low density lipoprotein (VLDL), low density lipoprotein (LDL),
and apolipoproteins. Endogenous cholesterol is synthesize in
hepatocytes via the mevalonate pathway.\(^{7,21}\) On the other hand,
exogenous cholesterol is endocytosed as the form of cholesteryl-
ester of LDL in hepatocytes and hydrolyzed to free cholesterol
and fatty acid.\(^{7,21}\) Because most of these metabolic processes of
lipid occur in the liver, serum TC level is closely related to the
severity of liver diseases.\(^{1,2}\)

Meanwhile, HCV has been documented to be able to inter-
rupt lipid metabolism directly. HCV binds to LDL receptors in
the membrane of hepatocytes for entry into the cells,\(^{7}\) and HCV
particles are released from hepatocytes via VLDL secretion path-
way.\(^{7,9,21}\) Moreover, HCV requires geranylgeranyl-pyrophosphate
(PP) in the mevalonate pathway for replication, which may
result in hypocholesterolemia, because HCV-infected cells spend
most of the mevalonate as a substrate for geranylgeranyl-PP,
rather than synthesis of cholesterol.\(^{7,21,24}\) Besides inhibition of
cholesterol synthesis, HCV could impede cholesterol secretion
into blood via the VLDL secretion pathway.\(^{21,25}\) These findings
suggest that HCV itself may play a role to induce hypocholes-
terolemia independent of hepatic fibrosis, however, it has not
been confirmed in human.

![Fig. 2.](image-url)
Many investigators have reported that reversals of hypocholesterolemia after antiviral therapy for CHC were observed among patient infected with HCV genotype 3, but there have been limited studies on the change of total cholesterol levels during and after antiviral therapy in genotype 1 and 2 infections.\(^1,11,13,14,26\) For the changing pattern of TC levels during antiviral therapy for genotype non-3 CHC, some studies have shown gradual increase of TC levels,\(^1,13\) while other studies\(^14,27\) have shown decrease of TC levels which was compatible with our results. The present study clearly showed that SVR resulted in reversal of hypocholesterolemia in patient infected mostly with genotype non-3 (98.9%).

On the other hands, the mechanism of reversal of hypocholesterolemia in HCV genotype non-3 infection can be different from that in genotype 3 infection. Thus, we hypothesized that the serum TC levels may increase after successful antiviral therapy by either eradication of HCV (SVR) or improvement of hepatic fibrosis which follows after viral eradication. To search the underlying reason for the increase of TC levels after SVR, we searched clinical variables associated with serum TC level, at pretreatment and post-treatment. Consequently, pretreatment TC level was inversely correlated with severity of liver fibrosis indicated as platelet count, METAVIR grade, Child-Pugh score and APRI. Although pretreatment TC level did not predict SVR in patients with genotype 1 or 2 infection, the elimination of hepatitis viruses from the liver was associated with the improvement of fibrosis grade and APRI. Those findings have not yet been sufficiently reported.

In addition, APRI scores decreased significantly in the SVR group than those in non-SVR group during and after antiviral therapy. As APRI is a simple and valid serum fibrosis marker,\(^20,28\) rapid reduction of APRI score may reflect a remarkably dynamic process related to improvement of liver fibrosis and inflammation during antiviral therapy. According to the multivariable analysis, APRI was the independent variable associated with the change of hepatic fibrosis. Therefore, the reversal of hypocholesterolemia in genotype 1 and 2 infected CHC after successful antiviral therapy may be mainly caused by improvement of hepatic fibrosis secondary to eradication of viruses rather than by direct effect of HCV eradication on cholesterol mechanism in CHC. However, further large prospective study is warranted to distinguish which factor plays the dominant role in increase of serum TC level after achieving SVR.

Among many other factors affecting serum cholesterol levels, such as race, age, gender, diabetes, and body mass index (BMI),\(^29\) BMI is one of the important determinants.\(^20,31\) Therefore, decreasing pattern of TC level during the antiviral therapy in our results is probably related to the decreased dietary intake and loss of body weight due to anorexia and other adverse effects of the therapy. However, age and BMI which were expected to affect serum TC levels significantly showed p-value less than 0.1 as the correlation analysis, probably due to small sample size.

The limitations of this study included retrospective design, relatively small sample size, and single center experience. The subgroup profiles of serum TC, which include LDL, VLDL, and high density lipoprotein, along with fasting glucose level were not available in the most of our subject patients due to retrospective design. We could not extensively investigate factors related to exogenous cholesterol uptake, such as dietary intake or body weight change during the course of antiviral therapy.

In conclusion, serum TC levels increased in the SVR group after antiviral therapy for CHC. The change may be explained by the improvement of liver fibrosis rather than by the eradication of HCV per se. Further investigation is needed to elucidate molecular mechanisms for the reversal of hypocholesterolemia in sustained viral responders, especially under the consideration of the change of hepatic fibrosis.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This study was supported in part by grants from Korea Center for Disease Control and Prevention, research No. 2009-S3-R. The authors thank the assistance and supports on the statistical analysis provided by Medical Research Collaborating Center of Seoul National University Hospital and Professor Weechang Kang in Department of Information and Statistics, Daejeon University.

REFERENCES

1. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157:792-796.
2. McIntyre N. Plasma lipids and lipoproteins in liver disease. Gut 1978;19:526-530.
3. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008;49:9-16.
4. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997;261:159-165.
5. Moriya K, Shintani Y, Fujie H, et al. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 2003;25:371-376.
6. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a
possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428-434.

7. Monazahian M, Kippenberger S, Müller A, et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol 2000;188:177-184.

8. Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006;13:56-61.

9. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog 2007;3:e108.

10. Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated hypocholesterolemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003;98:1150-1154.

11. Fernández-Rodríguez CM, López-Serrano P, Alonso S, et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006;24:507-512.

12. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.

13. Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol 1985;1:1-39.

14. Clouston AD, Jonsson JR, Purdie DM, et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-320.